small molecule glp-1 receptor agonist Orforglipron, an Oral Small-Molecule for Obesity November 5, 2025 DOI: 10.1056/NEJMdo008238 New for the treatment of obesity - and so many additional indications being studied A small-molecule oral agonist of
Description
Regarding co-agonist treatment, tirzepatide was recently shown in a post hoc analysis of the SURMOUNT-1 trial to also reduce UACR in overweight/obese people without T2D (88), and similar benefits for kidney function were shown in subjects with heart failure (89)
What's it going to do to me after 40 years of taking it
These medications work by mimicking natural hormones that regulate appetite and blood sugar levels
Consequently, a distinct meta-analysis comparing the effect of GLP-1 RAs versus metformin on CRP was feasible and performed
Its generally safe to combine fibre supplements with gentle osmotic laxatives, but always space them apart by at least 2 hours and consult your healthcare provider for personalised advice.
HR, 0.84 [95% CI, 0.72-0.98]
